MX358211B - Una composición farmacéutica de liberación comprendiendo hidroclorotiazida, losartán y basilato de amlodipino. - Google Patents

Una composición farmacéutica de liberación comprendiendo hidroclorotiazida, losartán y basilato de amlodipino.

Info

Publication number
MX358211B
MX358211B MX2012008541A MX2012008541A MX358211B MX 358211 B MX358211 B MX 358211B MX 2012008541 A MX2012008541 A MX 2012008541A MX 2012008541 A MX2012008541 A MX 2012008541A MX 358211 B MX358211 B MX 358211B
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
active principles
composition containing
release pharmaceutical
new differential
Prior art date
Application number
MX2012008541A
Other languages
English (en)
Other versions
MX2012008541A (es
Inventor
Martínez Reyes Julián
Alberto Reyes Romero Carlos
Peralta Agapito Darío
Original Assignee
Landsteiner Scient S A De C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Landsteiner Scient S A De C V filed Critical Landsteiner Scient S A De C V
Priority to MX2012008541A priority Critical patent/MX358211B/es
Priority to PCT/MX2013/000092 priority patent/WO2014017897A1/es
Priority to EP13822895.2A priority patent/EP2883546B1/en
Priority to JP2015524212A priority patent/JP6236079B2/ja
Priority to US14/416,475 priority patent/US20150190399A1/en
Priority to ES13822895T priority patent/ES2899885T3/es
Publication of MX2012008541A publication Critical patent/MX2012008541A/es
Publication of MX358211B publication Critical patent/MX358211B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a una formulación de liberación diferencial conteniendo un antagonista de los receptores de angiotensina II, un bloqueador de los canales de calcio y un diurético. Donde dicha composición farmacéutica permite la administración secuencial de los principios activos en una sola dosis de acuerdo a las necesidades del tratamiento.
MX2012008541A 2012-07-23 2012-07-23 Una composición farmacéutica de liberación comprendiendo hidroclorotiazida, losartán y basilato de amlodipino. MX358211B (es)

Priority Applications (6)

Application Number Priority Date Filing Date Title
MX2012008541A MX358211B (es) 2012-07-23 2012-07-23 Una composición farmacéutica de liberación comprendiendo hidroclorotiazida, losartán y basilato de amlodipino.
PCT/MX2013/000092 WO2014017897A1 (es) 2012-07-23 2013-07-22 Nueva composición farmacéutica de liberación diferencial conteniendo tres principios activos
EP13822895.2A EP2883546B1 (en) 2012-07-23 2013-07-22 New differential-release pharmaceutical composition containing three active principles
JP2015524212A JP6236079B2 (ja) 2012-07-23 2013-07-22 ３種の活性成分を含有する新規な時差放出医薬組成物
US14/416,475 US20150190399A1 (en) 2012-07-23 2013-07-22 New differential-release pharmaceutical composition containing three active principles
ES13822895T ES2899885T3 (es) 2012-07-23 2013-07-22 Nueva composición farmacéutica de liberación diferencial que contiene tres principios activos

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2012008541A MX358211B (es) 2012-07-23 2012-07-23 Una composición farmacéutica de liberación comprendiendo hidroclorotiazida, losartán y basilato de amlodipino.

Publications (2)

Publication Number Publication Date
MX2012008541A MX2012008541A (es) 2014-01-23
MX358211B true MX358211B (es) 2018-08-10

Family

ID=49997614

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012008541A MX358211B (es) 2012-07-23 2012-07-23 Una composición farmacéutica de liberación comprendiendo hidroclorotiazida, losartán y basilato de amlodipino.

Country Status (6)

Country Link
US (1) US20150190399A1 (es)
EP (1) EP2883546B1 (es)
JP (1) JP6236079B2 (es)
ES (1) ES2899885T3 (es)
MX (1) MX358211B (es)
WO (1) WO2014017897A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201991190A1 (ru) * 2016-11-15 2019-10-31 Фармацевтический комплексный препарат, содержащий амлодипин, лозартан и розувастатин
CN108785313A (zh) * 2018-07-06 2018-11-13 苏州大学附属第医院 一种药物组合物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5395626A (en) * 1994-03-23 1995-03-07 Ortho Pharmaceutical Corporation Multilayered controlled release pharmaceutical dosage form
EG24716A (en) * 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
US20050013863A1 (en) * 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
EP1680110B1 (en) * 2003-11-04 2011-01-05 Supernus Pharmaceuticals, Inc. Once daily dosage forms of trospium
US20050187262A1 (en) * 2004-01-12 2005-08-25 Grogan Donna R. Compositions comprising (S)-amlodipine and an angiotensin receptor blocker and methods of their use
KR20070058381A (ko) * 2004-04-27 2007-06-08 메디시노바, 인크. 염증성 질환 치료용 페녹시알킬카르복실 산 유도체
WO2005123042A1 (en) * 2004-06-10 2005-12-29 Glatt Air Techniques, Inc. Controlled release pharmaceutical formulation
CN103271920A (zh) * 2006-03-27 2013-09-04 威克斯医药有限公司 钠通道阻滞剂治疗由于化疗而产生的神经病理性疼痛的用途
PE20120542A1 (es) 2006-06-27 2012-05-14 Novartis Ag Formas de dosificacion solidas de valsartan, amlodipina e hidroclorotiazida y metodo para elaborarlas
KR100888131B1 (ko) * 2006-10-10 2009-03-11 한올제약주식회사 시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제
US20100143470A1 (en) * 2006-10-30 2010-06-10 Hanall Pharmaceutical Company, Ltd Controlled release pharmaceutical composition containing thiazides and angiotensin-ii-receptor blockers
US20090196907A1 (en) * 2008-01-31 2009-08-06 Bunick Frank J Edible film-strips for immediate release of active ingredients
US20090275559A1 (en) * 2008-04-30 2009-11-05 Blue Note Pharmaceuticals, Inc. Chronotherapeutic formulations of modified-release calcium channel blocker anti-hypertensive drugs in combination with other anti-hypertensive drugs for 24-hour optimal treatment of hypertension, nocturnal hypertension, and/or hypertension with angina
KR20090131472A (ko) * 2008-06-18 2009-12-29 삼천당제약주식회사 고혈압 치료용 약제학적 조성물 및 이를 이용한 제제
US20120107397A1 (en) * 2009-07-03 2012-05-03 Hetero Research Foundation Pharmaceutical compositions of valsartan
EP2632438A1 (en) 2010-10-27 2013-09-04 KRKA, tovarna zdravil, d.d., Novo mesto Multilayer pharmaceutical composition comprising telmisartan and amlodipine
US20140294959A1 (en) * 2011-05-20 2014-10-02 Astrazeneca Uk Limited Pharmaceutical Composition of Rosuvastatin Calcium

Also Published As

Publication number Publication date
ES2899885T3 (es) 2022-03-15
US20150190399A1 (en) 2015-07-09
EP2883546A1 (en) 2015-06-17
MX2012008541A (es) 2014-01-23
WO2014017897A1 (es) 2014-01-30
JP6236079B2 (ja) 2017-11-22
EP2883546B1 (en) 2021-09-08
JP2015522655A (ja) 2015-08-06
EP2883546A4 (en) 2016-05-18

Similar Documents

Publication Publication Date Title
GB2545368A (en) Diversion-resistant opioid formulations
PH12015501595A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12015501598A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12014502095A1 (en) Estrogen receptor modulators and uses thereof
PH12015501600A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
IL233592B (en) The compounds active as p2x4 receptor antagonists and substances containing them for the prevention and treatment of neurogenic pain
SG10201907588XA (en) Androgen Receptor Modulators And Uses Thereof
MY188450A (en) Spiro-lactam nmda receptor modulators and uses thereof
MX338515B (es) Derivados de tetrahidroquinolina utiles como inhibidores de bromodominio.
MX2013000567A (es) Composiciones farmaceuticas de moduladores de c-met.
GB201106750D0 (en) Novel compounds
MX359288B (es) Forma iv del clorhidrato de ivabradina.
EA201590805A1 (ru) Композиция с немедленным и пролонгированным высвобождением
MY166288A (en) Pharmaceutical composition comprising olmesartan medoxomil and rosuvastatin or its salt
DK201270677A (en) Pharmaceutical compositions comprising hydromorphone and naloxone
MY165888A (en) Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation
MY168212A (en) A new therapeutical composition containing apomorphine as active ingredient
EA201690679A1 (ru) Стабильная фармацевтическая композиция, содержащая амлодипин и валсартан
MX2016004741A (es) Composicion farmaceutica que comprende un antagonista de trpa1 y un agente analgesico.
PH12014501408A1 (en) Immediate release multi unit pellet system
MX2013013204A (es) Sistema de suministro de farmaco.
WO2012145575A3 (en) Therapy for leukemia
EA201590405A1 (ru) Приготовление высушенных липосом для применения в системах выпуска в прессованном виде
MX2016006603A (es) Compuestos piperidinicos con actividad multimodal contra el dolor.
MX2016007682A (es) Composicion farmaceutica que comprende ivabradina amorfa.

Legal Events

Date Code Title Description
FG Grant or registration